Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]
ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab